C3AR1 and early-onset autosomal dominant Alzheimer disease: As a proof of concept, C3aR antagonists have shown therapeutic benefit in a number of rodent models of Alzheimer’s disease and other disorders which pathologies also imply deregulation of ECM turnover and complement activation60–63.